Lexaria Bioscience Corp. (NASDAQ: LEXX) Concludes
Post# of 421
(Total Views: 168)
Posted On: 05/28/2024 5:19:19 PM
Lexaria Bioscience Corp. (NASDAQ: LEXX) Concludes First Dosing for its Second GLP-1 Human Pilot Study; Maintains Study Pace and Rollout for 2024
- Lexaria, a global innovator in drug delivery platforms, just concluded its first dosing for its glucagon-peptide-1 (“GLP-1”) human pilot study #2, GLP-1-H24-2
- GLP-1, a class of drugs, has demonstrated the ability to address diabetes and weight loss, albeit with poor oral bioavailability, usually as little as 0.8%
- Lexaria, through its study, looks to demonstrate the effectiveness of its DehydraTECH(TM) technology in improving GLP-1’s bioavailability, opening up a vast worldwide market
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just concluded its first dosing for its glucagon-peptide-1 (“GLP-1”) human pilot study #2, GLP-1-H24-2 (https://nnw.fm/yT9qj ). This follows the recent announcement of an applied research program to evaluate certain molecular characteristics of its patented DehydraTECH(TM) processed GLP-1 drug, semaglutide, related to its mode of action and performance. It also marks a significant milestone in the company’s 2024 research pipeline (https://nnw.fm/m48lH ).
At the beginning of the year, the company resolved to focus on GLP-1 studies for the calendar year, having shown positive results in an 8-week clinical study in 2023/24. This latest milestone followed its recent contract award and independent ethics review board approval in April.
The study will spot three arms, comparing 7 mg semaglutide dose formulations. The first arm used a positive control Rybelsus(R) swallowed tablet, while the second arm – due to be performed in late June – will feature DehydraTECH-semaglutide swallowed capsules. Nearly 5 weeks are required between doses to “wash-out” lingering quantities of drugs between study arms.
The last arm will, for the first time, utilize an in-mouth dissolvable DehydraTECH-semaglutide oral tablet. This study arm will investigate whether DehydraTECH-enhanced semaglutide can be absorbed at any level systemically through the sublingual/buccal tissues of the mouth and throat, and into the bloodstream, with fewer side effects than from swallowed pill administration. It will mostly avoid the stomach’s acidic environment, which seriously degrades GLP-1 drugs that are swallowed, resulting in exceptionally low blood absorption rates.
GLP-1 exhibits poor oral bioavailability, usually as little as 0.8%, despite having demonstrated the ability to address diabetes and weight loss. Lexaria, through its DehydraTECH technology, has proven to significantly improve this bioavailability.
Lexaria looks to follow through with this clinical study, and more, ultimately carving out a significant market share in the diabetes treatment market, projected to reach $134.1 billion by 2030. Its management is optimistic that this will be its biggest year yet, where all its efforts and investments will pay off.
“I am excited about this study; the Lexaria scientific team believes that a dissolvable oral tablet that delivers an effective fraction of semaglutide along with reduced side effects could potentially offer valuable benefits to the pharmaceutical industry that might lead to a higher likelihood of favorable strategic partnering with leading industry players in GLP-1,” noted Chris Bunka, Lexaria’s CEO (https://nnw.fm/w6WfO ).
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://nnw.fm/LEXX
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
- Lexaria, a global innovator in drug delivery platforms, just concluded its first dosing for its glucagon-peptide-1 (“GLP-1”) human pilot study #2, GLP-1-H24-2
- GLP-1, a class of drugs, has demonstrated the ability to address diabetes and weight loss, albeit with poor oral bioavailability, usually as little as 0.8%
- Lexaria, through its study, looks to demonstrate the effectiveness of its DehydraTECH(TM) technology in improving GLP-1’s bioavailability, opening up a vast worldwide market
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just concluded its first dosing for its glucagon-peptide-1 (“GLP-1”) human pilot study #2, GLP-1-H24-2 (https://nnw.fm/yT9qj ). This follows the recent announcement of an applied research program to evaluate certain molecular characteristics of its patented DehydraTECH(TM) processed GLP-1 drug, semaglutide, related to its mode of action and performance. It also marks a significant milestone in the company’s 2024 research pipeline (https://nnw.fm/m48lH ).
At the beginning of the year, the company resolved to focus on GLP-1 studies for the calendar year, having shown positive results in an 8-week clinical study in 2023/24. This latest milestone followed its recent contract award and independent ethics review board approval in April.
The study will spot three arms, comparing 7 mg semaglutide dose formulations. The first arm used a positive control Rybelsus(R) swallowed tablet, while the second arm – due to be performed in late June – will feature DehydraTECH-semaglutide swallowed capsules. Nearly 5 weeks are required between doses to “wash-out” lingering quantities of drugs between study arms.
The last arm will, for the first time, utilize an in-mouth dissolvable DehydraTECH-semaglutide oral tablet. This study arm will investigate whether DehydraTECH-enhanced semaglutide can be absorbed at any level systemically through the sublingual/buccal tissues of the mouth and throat, and into the bloodstream, with fewer side effects than from swallowed pill administration. It will mostly avoid the stomach’s acidic environment, which seriously degrades GLP-1 drugs that are swallowed, resulting in exceptionally low blood absorption rates.
GLP-1 exhibits poor oral bioavailability, usually as little as 0.8%, despite having demonstrated the ability to address diabetes and weight loss. Lexaria, through its DehydraTECH technology, has proven to significantly improve this bioavailability.
Lexaria looks to follow through with this clinical study, and more, ultimately carving out a significant market share in the diabetes treatment market, projected to reach $134.1 billion by 2030. Its management is optimistic that this will be its biggest year yet, where all its efforts and investments will pay off.
“I am excited about this study; the Lexaria scientific team believes that a dissolvable oral tablet that delivers an effective fraction of semaglutide along with reduced side effects could potentially offer valuable benefits to the pharmaceutical industry that might lead to a higher likelihood of favorable strategic partnering with leading industry players in GLP-1,” noted Chris Bunka, Lexaria’s CEO (https://nnw.fm/w6WfO ).
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://nnw.fm/LEXX
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
(0)
(0)